Audio-Described Menopause Education Program in Visually Impaired Women
17 de agosto de 2026 atualizado por: İlknur Münevver Gönenç, Ankara University
The Effect of Education Provided Through Audio Description Method on Menopause Knowledge and Menopausal Symptoms in Visually Impaired Women: Randomized Controlled Trial
This randomized controlled trial was conducted to evaluate the effect of an audio-described menopause education program on menopause knowledge and menopausal symptoms in women with visual impairment.
A total of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association were randomly assigned to either an intervention group (n=23) or a control group (n=23).
The intervention group received an accessible menopause education program, while the control group did not receive the intervention during the study period.
Outcomes included menopause knowledge and menopausal symptom severity, assessed using standardized measurement tools.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Descrição detalhada
This study was designed as a randomized controlled trial in accordance with CONSORT guidelines. It aimed to determine the effectiveness of an audio-described menopause symptom and awareness education program for women with visual impairment on menopause knowledge and menopausal symptoms.
The study sample consisted of 46 women who were members of the Ankara Branch of the Altı Nokta Blind Association. Participants were randomly allocated in a 1:1 ratio to either the intervention group (n=23) or the control group (n=23).
Data were collected using a demographic information form, the Menopause Knowledge Scale, and the Menopause Rating Scale. The intervention group received an audio-described educational program designed to improve accessibility for women with visual impairment, while the control group did not receive the intervention during the study period.
Statistical analyses included descriptive statistics, Fisher-Freeman-Halton Exact test, Pearson chi-square test, Cronbach's alpha reliability analysis, assessment of skewness and kurtosis for normality, Pearson correlation analysis, independent samples t-test, and analysis of covariance (ANCOVA). Statistical significance was set at p < 0.05.
Tipo de estudo
Intervencional
Inscrição (Real)
46
Estágio
- Não aplicável
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
Altindağ
-
Ankara, Altindağ, Turquia (Türkiye), 06250
- Ankara University
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
Aceita Voluntários Saudáveis
Não
Descrição
Inclusion Criteria:
- Being a member of the Ankara Branch of the Altı Nokta Blind Association,
- Being a woman with visual impairment (congenital or acquired),
- Being female,
- Being between 40 and 60 years of age,
- Being able to speak Turkish,
- Having no additional communication problems other than visual impairment,
- Having experienced at least 12 months of amenorrhea (STRAW+1 criteria).
Exclusion Criteria:
- Refusal to participate in the study,
- Previous participation in a structured menopause-related education program,
- Use of pharmacological treatment for the management of menopausal symptoms,
- Use of non-pharmacological methods for menopausal symptom management (e.g., yoga, aromatherapy, phytotherapy, etc.),
- Surgical menopause,
- Having additional disabilities other than visual impairment (hearing, intellectual, or physical disabilities).
Withdrawal / Discontinuation Criteria
- Initiation of any pharmacological or non-pharmacological intervention aimed at reducing menopausal symptoms during the study period,
- Non-adherence to the study protocol,
- Voluntary withdrawal from the study.
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Cuidados de suporte
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Audio description-based menopause education program
Participants in this arm received an audio-described menopause education program designed for women with visual impairment.
The intervention aimed to improve menopause knowledge and reduce menopausal symptom-related difficulties.
The educational content was delivered in an accessible format tailored to participants' needs.
Outcomes were assessed using standardized measurement tools.
|
This intervention consisted of a structured audio-described menopause education program developed for women with visual impairment.
The program provided accessible information about menopause, menopausal symptoms, and symptom management strategies to improve knowledge and awareness.
|
|
Sem intervenção: Standard of care
Participants in this arm did not receive the audio-described menopause education program during the study period.
They continued with their usual daily life without any structured educational intervention related to menopause.
Outcomes were assessed at the same time points using standardized measurement tools.
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Menopause Knowledge
Prazo: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
To assess changes in menopause knowledge following the audio-described menopause education program.
The total score of the "Menopause Knowledge Scale" ranges from 14 to 70, with higher scores indicating a higher level of overall knowledge about menopause.
Similarly, higher scores on the General Menopause Knowledge subscale (5-25) and the Knowledge of Menopausal Symptoms and Management subscale (9-45) indicate greater knowledge in the respective domains.
|
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
|
Menopausal Symptom Severity
Prazo: Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
To evaluate changes in menopausal symptom severity following the audio-described menopause education program.
The Menopause Rating Scale was used to assess the severity of menopausal symptoms.The total score of the scale ranges from 0 to 44.
Higher total scores indicate greater severity of menopausal symptoms and a more negative impact on quality of life.
|
Measured at three time points: baseline (pre-test), immediately after the intervention (T1), and 1 month post-intervention (T2).
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo (Real)
15 de fevereiro de 2025
Conclusão Primária (Real)
15 de julho de 2025
Conclusão do estudo (Real)
15 de julho de 2025
Datas de inscrição no estudo
Enviado pela primeira vez
3 de julho de 2026
Enviado pela primeira vez que atendeu aos critérios de CQ
17 de agosto de 2026
Primeira postagem (Real)
19 de agosto de 2026
Atualizações de registro de estudo
Última Atualização Postada (Real)
19 de agosto de 2026
Última atualização enviada que atendeu aos critérios de controle de qualidade
17 de agosto de 2026
Última verificação
1 de agosto de 2026
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- Ankara University Thesis
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
SIM
Descrição do plano IPD
De-identified participant data, including baseline characteristics and outcome measures, will be shared.
No identifiable personal data will be included.
Prazo de Compartilhamento de IPD
De-identified individual participant data will be available beginning 6 months after publication of the study results and will remain available for 5 years.
Critérios de acesso de compartilhamento IPD
Access to individual participant data and supporting documents will be granted to qualified researchers who submit a methodologically sound research proposal.
Requests must be approved by the principal investigator or study sponsor.
Data will be provided for non-commercial academic research purposes only.
All data will be de-identified, and no personally identifiable information will be shared.
Data will be shared via secure electronic transfer upon approval.
Tipo de informação de suporte de compartilhamento de IPD
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Não
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Não
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .